Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat?

Jane Valentine, Sue Anne Davidson, Natasha Bear, Eve Blair, Roslyn Ward, Ashleigh Thornton, Katherine Stannage, Linda Watson, David Forbes, Catherine Elliott

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: This audit aimed to increase understanding of the long-term outcomes of evidence-based medical and surgical interventions to improve gross motor function in children and adolescents with Cerebral Palsy. Methods: Retrospective audit of a birth cohort (2000–2009) attending a tertiary service in Western Australia. Results: The cohort comprises 771 patients aged 8 to 17 years. Percentage of children receiving no Botulinum Toxin treatments in each Gross Motor Functional Classification System level was: I: 40%, II: 26%, III: 33%, IV: 28% and V: 46%. Of the total cohort, 53% of children received 4 or less Botulinum Toxin treatments and 3.7% received more than 20 treatments. Statistically significant difference in the rate of use of Botulinum Toxin pre and post-surgery (p <0.001) was documented. Children levels IV and V had 5 times the odds of surgery compared to children levels I–III (Odds Ratio 5.2, 95% Confidence Interval 3.5 to 7.8, p <0.001). For 578 (75%) of participants the last recorded level was the same as the first. Conclusion: This audit documents medical intervention by age and Gross Motor Functional Classification System level in a large cohort of children with cerebral palsy over time and confirms stability of the level in the majority.IMPLICATIONS FOR REHABILITATION The information from this audit may be of use in discussions with families regarding the timing and use of Botulinum toxin and surgical intervention for motor function in children and adolescents with Cerebral Palsy. Long term use of Botulinum Toxin within an integrated evidence-based clinical program is not associated with loss of gross motor function in the long term as evidenced by the maintenance of Gross Motor Functional Classification System stability.

Original languageEnglish
JournalDisability and Rehabilitation
DOIs
Publication statusE-pub ahead of print - 15 Aug 2019

Fingerprint

Botulinum Toxins
Cerebral Palsy
Medical Audit
Western Australia
Therapeutics
Rehabilitation
Odds Ratio
Maintenance
Parturition
Confidence Intervals

Cite this

@article{e6fea385a2214c4dbafbd293f05c472b,
title = "Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat?",
abstract = "Introduction: This audit aimed to increase understanding of the long-term outcomes of evidence-based medical and surgical interventions to improve gross motor function in children and adolescents with Cerebral Palsy. Methods: Retrospective audit of a birth cohort (2000–2009) attending a tertiary service in Western Australia. Results: The cohort comprises 771 patients aged 8 to 17 years. Percentage of children receiving no Botulinum Toxin treatments in each Gross Motor Functional Classification System level was: I: 40{\%}, II: 26{\%}, III: 33{\%}, IV: 28{\%} and V: 46{\%}. Of the total cohort, 53{\%} of children received 4 or less Botulinum Toxin treatments and 3.7{\%} received more than 20 treatments. Statistically significant difference in the rate of use of Botulinum Toxin pre and post-surgery (p <0.001) was documented. Children levels IV and V had 5 times the odds of surgery compared to children levels I–III (Odds Ratio 5.2, 95{\%} Confidence Interval 3.5 to 7.8, p <0.001). For 578 (75{\%}) of participants the last recorded level was the same as the first. Conclusion: This audit documents medical intervention by age and Gross Motor Functional Classification System level in a large cohort of children with cerebral palsy over time and confirms stability of the level in the majority.IMPLICATIONS FOR REHABILITATION The information from this audit may be of use in discussions with families regarding the timing and use of Botulinum toxin and surgical intervention for motor function in children and adolescents with Cerebral Palsy. Long term use of Botulinum Toxin within an integrated evidence-based clinical program is not associated with loss of gross motor function in the long term as evidenced by the maintenance of Gross Motor Functional Classification System stability.",
keywords = "botulinum toxin, Cerebral palsy, children, gross motor function classification, orthopedic surgery",
author = "Jane Valentine and Davidson, {Sue Anne} and Natasha Bear and Eve Blair and Roslyn Ward and Ashleigh Thornton and Katherine Stannage and Linda Watson and David Forbes and Catherine Elliott",
year = "2019",
month = "8",
day = "15",
doi = "10.1080/09638288.2019.1644381",
language = "English",
journal = "Disability & Rehabilitation",
issn = "0963-8288",
publisher = "Taylor & Francis",

}

Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy : who, when and why do we treat? / Valentine, Jane; Davidson, Sue Anne; Bear, Natasha; Blair, Eve; Ward, Roslyn; Thornton, Ashleigh; Stannage, Katherine; Watson, Linda; Forbes, David; Elliott, Catherine.

In: Disability and Rehabilitation, 15.08.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy

T2 - who, when and why do we treat?

AU - Valentine, Jane

AU - Davidson, Sue Anne

AU - Bear, Natasha

AU - Blair, Eve

AU - Ward, Roslyn

AU - Thornton, Ashleigh

AU - Stannage, Katherine

AU - Watson, Linda

AU - Forbes, David

AU - Elliott, Catherine

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Introduction: This audit aimed to increase understanding of the long-term outcomes of evidence-based medical and surgical interventions to improve gross motor function in children and adolescents with Cerebral Palsy. Methods: Retrospective audit of a birth cohort (2000–2009) attending a tertiary service in Western Australia. Results: The cohort comprises 771 patients aged 8 to 17 years. Percentage of children receiving no Botulinum Toxin treatments in each Gross Motor Functional Classification System level was: I: 40%, II: 26%, III: 33%, IV: 28% and V: 46%. Of the total cohort, 53% of children received 4 or less Botulinum Toxin treatments and 3.7% received more than 20 treatments. Statistically significant difference in the rate of use of Botulinum Toxin pre and post-surgery (p <0.001) was documented. Children levels IV and V had 5 times the odds of surgery compared to children levels I–III (Odds Ratio 5.2, 95% Confidence Interval 3.5 to 7.8, p <0.001). For 578 (75%) of participants the last recorded level was the same as the first. Conclusion: This audit documents medical intervention by age and Gross Motor Functional Classification System level in a large cohort of children with cerebral palsy over time and confirms stability of the level in the majority.IMPLICATIONS FOR REHABILITATION The information from this audit may be of use in discussions with families regarding the timing and use of Botulinum toxin and surgical intervention for motor function in children and adolescents with Cerebral Palsy. Long term use of Botulinum Toxin within an integrated evidence-based clinical program is not associated with loss of gross motor function in the long term as evidenced by the maintenance of Gross Motor Functional Classification System stability.

AB - Introduction: This audit aimed to increase understanding of the long-term outcomes of evidence-based medical and surgical interventions to improve gross motor function in children and adolescents with Cerebral Palsy. Methods: Retrospective audit of a birth cohort (2000–2009) attending a tertiary service in Western Australia. Results: The cohort comprises 771 patients aged 8 to 17 years. Percentage of children receiving no Botulinum Toxin treatments in each Gross Motor Functional Classification System level was: I: 40%, II: 26%, III: 33%, IV: 28% and V: 46%. Of the total cohort, 53% of children received 4 or less Botulinum Toxin treatments and 3.7% received more than 20 treatments. Statistically significant difference in the rate of use of Botulinum Toxin pre and post-surgery (p <0.001) was documented. Children levels IV and V had 5 times the odds of surgery compared to children levels I–III (Odds Ratio 5.2, 95% Confidence Interval 3.5 to 7.8, p <0.001). For 578 (75%) of participants the last recorded level was the same as the first. Conclusion: This audit documents medical intervention by age and Gross Motor Functional Classification System level in a large cohort of children with cerebral palsy over time and confirms stability of the level in the majority.IMPLICATIONS FOR REHABILITATION The information from this audit may be of use in discussions with families regarding the timing and use of Botulinum toxin and surgical intervention for motor function in children and adolescents with Cerebral Palsy. Long term use of Botulinum Toxin within an integrated evidence-based clinical program is not associated with loss of gross motor function in the long term as evidenced by the maintenance of Gross Motor Functional Classification System stability.

KW - botulinum toxin

KW - Cerebral palsy

KW - children

KW - gross motor function classification

KW - orthopedic surgery

UR - http://www.scopus.com/inward/record.url?scp=85070927170&partnerID=8YFLogxK

U2 - 10.1080/09638288.2019.1644381

DO - 10.1080/09638288.2019.1644381

M3 - Article

JO - Disability & Rehabilitation

JF - Disability & Rehabilitation

SN - 0963-8288

ER -